China Resources Pharmaceutical Group Limited (stock code: 03320.HK) disclosed key figures from its A-share subsidiary Dong-E-E-Jiao Co., Ltd.’s audited results for the year ended 31 December 2025.

Financial highlights • Revenue reached RMB 6.70 billion, an 8.83% increase year on year. • Net profit attributable to shareholders rose 11.66% to RMB 1.74 billion. • Net profit excluding extraordinary gains and losses grew 13.62% to RMB 1.64 billion. • Basic and diluted EPS were both RMB 2.70, up 11.57%. • Weighted average ROE improved by 2.10 percentage points to 16.66%.

Balance-sheet movements • Total assets expanded 2.18% to RMB 13.38 billion. • Net assets attributable to shareholders edged up 0.20% to RMB 10.34 billion.

Cash flow • Net cash generated from operating activities declined 19.70% to RMB 2.29 billion.

Dividend proposal Dong-E-E-Jiao’s board recommends a cash dividend of RMB 14.31 (tax inclusive) for every 10 shares, subject to approval at the 2025 annual general meeting.

Equity structure China Resources Pharma directly holds 10.19% of Dong-E-E-Jiao and, through its non-wholly-owned subsidiary China Resources Dong-E-E-Jiao Co., Ltd., effectively controls 23.50% of the A-share company. Dong-E-E-Jiao is consolidated as a subsidiary in China Resources Pharma’s financial statements.

The disclosed figures are prepared in accordance with PRC GAAP and relate solely to Dong-E-Jiao; they do not constitute a full picture of China Resources Pharma’s consolidated results. Investors are advised to refer to Dong-E-E-Jiao’s 2025 annual report published on the Shenzhen Stock Exchange website for complete details.